PL3402821T3 - Przeciwciało wiążące psma i jego zastosowania - Google Patents

Przeciwciało wiążące psma i jego zastosowania

Info

Publication number
PL3402821T3
PL3402821T3 PL17701290.3T PL17701290T PL3402821T3 PL 3402821 T3 PL3402821 T3 PL 3402821T3 PL 17701290 T PL17701290 T PL 17701290T PL 3402821 T3 PL3402821 T3 PL 3402821T3
Authority
PL
Poland
Prior art keywords
psma
applications
binding antibody
antibody
binding
Prior art date
Application number
PL17701290.3T
Other languages
English (en)
Inventor
Helmut Salih
Fabian Vogt
Gundram Jung
Latifa ZEKRI-METREF
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Eberhard Karls Universität Tübingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Eberhard Karls Universität Tübingen filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of PL3402821T3 publication Critical patent/PL3402821T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17701290.3T 2016-01-14 2017-01-16 Przeciwciało wiążące psma i jego zastosowania PL3402821T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151281.9A EP3192810A1 (en) 2016-01-14 2016-01-14 Psma binding antibody and uses thereof
PCT/EP2017/050834 WO2017121905A1 (en) 2016-01-14 2017-01-16 Psma binding antibody and uses thereof

Publications (1)

Publication Number Publication Date
PL3402821T3 true PL3402821T3 (pl) 2024-03-04

Family

ID=55349634

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17701290.3T PL3402821T3 (pl) 2016-01-14 2017-01-16 Przeciwciało wiążące psma i jego zastosowania

Country Status (16)

Country Link
US (3) US11612646B2 (pl)
EP (3) EP3192810A1 (pl)
JP (1) JP6893939B2 (pl)
CN (1) CN108699157B (pl)
AU (2) AU2017207947B9 (pl)
CA (2) CA3011098A1 (pl)
DK (1) DK3402821T5 (pl)
ES (1) ES2963561T3 (pl)
FI (1) FI3402821T3 (pl)
HU (1) HUE064205T2 (pl)
IL (1) IL260402B2 (pl)
PL (1) PL3402821T3 (pl)
PT (1) PT3402821T (pl)
RU (1) RU2762704C2 (pl)
WO (1) WO2017121905A1 (pl)
ZA (1) ZA201804601B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
IL279354B1 (en) * 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
EP4255482A1 (en) * 2020-12-01 2023-10-11 The Johns Hopkins University Methods and materials for treating t cell cancers
IL303328A (en) * 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
CN112480260B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用
EP4284838A2 (en) * 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
TW202515907A (zh) * 2023-08-23 2025-04-16 日商明治制果藥業股份有限公司 新穎抗切斷型突變calr-cd3雙特異性抗體及醫藥組合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
JP2012511024A (ja) * 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
WO2015006749A2 (en) * 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding contructs
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
EP3119902A4 (en) * 2014-03-18 2017-11-29 Aptevo Research and Development LLC Cell line-based redirected t-cell cytotoxicity assay
SI3132247T1 (sl) 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof

Also Published As

Publication number Publication date
ZA201804601B (en) 2019-04-24
CN108699157A (zh) 2018-10-23
FI3402821T3 (fi) 2023-10-26
US20250346669A1 (en) 2025-11-13
US20190022205A1 (en) 2019-01-24
EP3402821B1 (en) 2023-08-23
JP6893939B2 (ja) 2021-06-23
AU2017207947A1 (en) 2018-07-26
WO2017121905A1 (en) 2017-07-20
HUE064205T2 (hu) 2024-02-28
DK3402821T5 (da) 2024-09-23
US12398208B2 (en) 2025-08-26
NZ744221A (en) 2025-07-25
BR112018014215A2 (pt) 2018-12-26
RU2018128414A3 (pl) 2020-10-20
CN108699157B (zh) 2022-02-01
JP2019505589A (ja) 2019-02-28
EP3402821A1 (en) 2018-11-21
AU2017207947B9 (en) 2023-09-21
CA3199697A1 (en) 2017-07-20
AU2023203041A1 (en) 2023-06-08
EP3192810A1 (en) 2017-07-19
ES2963561T3 (es) 2024-03-27
EP3693396A3 (en) 2020-10-14
US20230132249A1 (en) 2023-04-27
RU2018128414A (ru) 2020-02-14
IL260402A (pl) 2018-08-30
EP3693396A2 (en) 2020-08-12
IL260402B2 (en) 2023-12-01
DK3402821T3 (da) 2023-11-06
US11612646B2 (en) 2023-03-28
CA3011098A1 (en) 2017-07-20
AU2017207947B2 (en) 2023-09-07
IL260402B1 (en) 2023-08-01
RU2762704C2 (ru) 2021-12-22
PT3402821T (pt) 2023-09-26

Similar Documents

Publication Publication Date Title
PL3402821T3 (pl) Przeciwciało wiążące psma i jego zastosowania
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL262095A (en) Anti-pacap antibodies and uses thereof
IL264011A (en) Antibodies against tim3 and uses thereof
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
IL257324A (en) Antibody against glypican-3 and application thereof
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
DK3625259T3 (da) Anti-sirpalpha-antistoffer
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
DK3529269T3 (da) Antistof-konstruktioner
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
IL256099A (en) Antibody
DK3606961T3 (da) Garp-tgf-beta-antistoffer
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3710486C0 (en) X-Factor Antibodies
IL262251B1 (en) New anti-sirpa antibodies and their therapeutic applications
DK3359563T3 (da) Antigenreceptorer og anvendelser deraf
EP3672987C0 (en) ANTI-APELIN ANTIBODIES AND THEIR USES
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
PL3455261T3 (pl) Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
IL257368A (en) Antibody
DK3245219T3 (da) Glypicanepitoper og anvendelser deraf
EP3579879A4 (en) ANTI-BODY ANTI-KIR3DL1